TVTX

Travere Therapeutics, Inc.

8.19 USD
+0.32 (+4.07%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Travere Therapeutics, Inc. stock is down -0.85% since 30 days ago. The next earnings date is May 2, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 20 March’s closed higher than February. In the last 4 Unusual Options Trades, there were 3 CALLs, 1 PUT. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
12 Jan 20:22 16 Feb, 2024 10.00 CALL 248 41
16 Jan 16:09 20 Dec, 2024 10.00 PUT 563 0
24 Jan 16:30 21 Jun, 2024 5.00 CALL 90 318
24 Jan 16:31 21 Jun, 2024 5.00 CALL 100 318

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.

  • Wells Fargo
    Fri Feb 16, 13:44
    hold
    confirm
  • Wedbush
    Fri Feb 16, 08:56
    buy
    confirm